Atherosclerosis · Nov 2026

The Clinical Relevance of Lipoprotein(a) in the Post-Lp(a)HORIZON Era: A Statement of the European Atherosclerosis Society

By Laufs U, Nordestgaard BG, Mora S et al.

Considering the recent Lp(a)HORIZON trial results showing that pelacarsen with 78% lowering of lipoprotein(a) in patients with atherosclerotic cardiovascular disease did not further reduce such events, the European Atherosclerosis Society (EAS) underscores that high lipoprotein(a) remains a genetically determined risk modifier of cardiovascular disease independently of LDL cholesterol concentrations and other traditional risk factors. The EAS maintains its recommendation for one-time universal lipoprotein(a) testing to assess individual cardiovascular risk, to guide preventive strategies - especially optimal LDL cholesterol lowering - and to facilitate family screening. The EAS acknowledges key unresolved questions and advocates for sustained research and future clinical trials on lipoprotein(a) lowering to reduce the burden of cardiovascular disease.

doi.org/10.1016/j.atherosclerosis.2026.121955Open accessIndustry & policy

AgingResearch.News